Chikungunya virus infected cells

Chikungunya virus infected cells" is not a specific therapeutic target such as a receptor, enzyme, or transporter, but rather a descriptive term referring to host cells (e.g., fibroblasts, macrophages, endothelial cells) productively infected by the Chikungunya virus (CHIKV), an alphavirus transmitted by Aedes mosquitoes.[1][4][12] CHIKV exhibits tropism for mesenchymal tissues including skin fibroblasts, adipocytes, synovial cells, and mononuclear cells like macrophages and dendritic cells, leading to viral replication complexes (spherules) at the plasma membrane where non-structural proteins nsP1, nsP2, and nsP4 form the core RNA replicase for genome amplification.[1][2][12] Infection triggers acute symptoms like fever, polyarthralgia, myalgia, rash, and in severe cases, fatal outcomes from septic shock, pulmonary edema, or multi-organ involvement with histopathologic changes such as tenosynovitis, hemorrhage, and immunoblast proliferation.[1][3][6] While antiviral host responses (e.g., IFN signaling via STAT1/IRF, inflammasome activation) occur in these cells, no direct small-molecule drugs target the infected cells themselves; therapies focus on supportive care or virus components like nsP proteins or entry receptors (e.g., MXRA8, though not specified here).[2][3][4] This term is imprecise for drug targeting, as therapeutic strategies aim at viral proteins or host factors rather than the infected cell state.[2][5][7]

Other names

CHIKV-infected cells